Baseline characteristics of included patients
| Variable | Total (N=456) | MACE at 30 days (N=97) | No MACE at 30 days (N=359) |
|---|---|---|---|
| Age in years, mean (SD) | 64 (16) | 71 (13) | 62 (16) |
| Men (%) | 264 (57.9) | 60 (61.9) | 204 (56.8) |
| Previous angina (%) | 185 (40.6) | 32 (33.0) | 153 (42.6) |
| Previous myocardial infarction (%) | 139 (30.5) | 34 (35.1) | 105 (29.2) |
| Hypertension (%) | 192 (42.1) | 52 (53.6) | 140 (39.0) |
| Hyperlipidaemia (%) | 183 (40.1) | 44 (45.4) | 139 (38.7) |
| Diabetes mellitus (%) | 78 (17.1) | 25 (25.8) | 53 (14.8) |
| Smoking (%) | 94 (20.6) | 20 (20.6) | 74 (20.6) |
| Previous coronary intervention (%) | 67 (14.7) | 14 (14.4) | 53 (14.8) |
| Cerebrovascular disease (%) | 30 (6.6) | 5 (5.2) | 25 (7.0) |
| Components of the MACS rule: | |||
| Worsening angina | 95 (20.8) | 27 (27.8) | 68 (18.9) |
| Hypotension | 17 (3.7) | 4 (4.1) | 13 (3.6) |
| Radiation to the right arm/shoulder | 59 (12.9) | 23 (23.7) | 36 (10.0) |
| Pain associated with vomiting | 32 (7.0) | 10 (10.3) | 22 (6.1) |
| Sweating observed | 24 (5.3) | 12 (12.4) | 12 (3.3) |
| ECG ischaemia | 102 (22.4) | 42 (43.3) | 60 (16.7) |
| h-FABP (Randox IT assay, ng/mL; median, IQR) | 5.3 (3.7–7.9) | 11.1 (7.0–21.1) | 4.6 (3.5–6.5) |
| hs-cTnT (ng/L, median, IQR) | 9.8 (5.3–23.1) | 64.9 (27.3–108.4) | 7.6 (4.9–14.4) |
h-FABP, heart-type fatty acid binding protein; hs-cTnT, high sensitivity troponin T; MACE, major adverse cardiac events; MACS, Manchester Acute Coronary Syndromes.